The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...

Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal on Thursday to slash the prices of popular GLP-1 ...

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Shares in Novo Nordisk fell as much as 3 per cent on Friday after the Danish drugmaker and U.S. rival Eli Lilly agreed with ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...

The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

Oz acknowledged obesity isn't "a deficiency of GLP drugs" but called reducing costs "a belt-and-suspenders approach." ...